Dermatologic complications of anti-PD-1/PD-L1 immune checkpoint antibodies

Current Opinion in Oncology

Volumn 28, Issue 4, 2016, Pages 254-263

  Sibaud, Vincent ^a   Meyer, Nicolas ^a   Lamant, Laurence ^a   Vigarios, Emmanuelle ^a   Mazieres, Julien ^b   Delord, Jean Pierre ^a  

^a INSTITUT CLAUDIUS REGAUD   (France)

^b UNIVERSITÉ DE TOULOUSE   (France)

Author keywords

anti PD 1 PD L1; lichenoid; mucosa; psoriasis; skin toxicities

Indexed keywords

ANTINEOPLASTIC AGENT; IPILIMUMAB; MONOCLONAL ANTIBODY; PD L1 IMMMUNE CHECKPOINT BLOCKING ANTIBODY; UNCLASSIFIED DRUG; CARRIER PROTEIN; CD274 PROTEIN, HUMAN; CHOLINE TRANSPORTER-LIKE PROTEIN 4, HUMAN; NIVOLUMAB; PEMBROLIZUMAB; PROGRAMMED DEATH 1 LIGAND 1;

ADVERSE DRUG REACTION; AUTOIMMUNE DISEASE; CANCER CHEMOTHERAPY; CANCER PATIENT; CLINICAL FEATURE; DRUG SAFETY; DRUG WITHDRAWAL; DYSGEUSIA; HUMAN; IMMUNE RELATED ADVERSE EVENT; IMMUNOPATHOLOGY; INCIDENCE; LICHENOID; LICHENOID ERUPTION; MACULOPAPULAR RASH; MELANOMA; MORBIDITY; MUCOSA; PRIORITY JOURNAL; PRURITUS; PSORIASIS; RASH; REVIEW; SKIN MANIFESTATION; SKIN TOXICITY; T LYMPHOCYTE ACTIVATION; VITILIGO; XEROSIS; XEROSTOMIA; ANTAGONISTS AND INHIBITORS; DRUG ERUPTIONS; IMMUNOLOGY;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIGENS, CD274; DRUG ERUPTIONS; HUMANS; MELANOMA; MEMBRANE TRANSPORT PROTEINS;

EID: 84964777630     PISSN: 10408746     EISSN: 1531703X     Source Type: Journal    
DOI: 10.1097/CCO.0000000000000290     Document Type: Review

References (37)

1. Postow MA. Managing immune checkpoint-blocking antibody side effects. Am Soc Clin Oncol Educ Book 2015; 35:2092-2099.
2. Naidoo J, Page DB, Li BT, et al. Toxicities of the anti-PD-1 and anti PD-L1 immune checkpoint antibodies. Ann Oncol 2015; 26:2375-2391.
3. Larkin J, Lao CD, Urba WJ, et al. Efficacy and safety of nivolumab in patients with BRAF V600 mutant and BRAF wild-type advanced melanoma: a pooled analysis of 4 clinical trials. JAMA Oncol 2015; 1:433-440.
4. Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2015; 372:320-330.
5. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015; 373:23-34.
6. Freeman-Keller M, Kim Y, Cronin H, et al. Nivolumab in resected and unresectable metastatic melanoma: characteristics of immune-related adverse events and association with outcomes. Clin Cancer Res 2016; 22:886-894. [Epub ahead of print]
7. Robert C, Schachter J, Long GV, et al. pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 2015; 372:2521-2532.
8. Ciccarese C, Alfieri S, Santoni M, et al. New toxicity profile for novel immunotherapy agents: focus on immune-checkpoint inhibitors. Expert Opin Drug Metab Toxicol 2016; 12:57-75.
9. McDermott DF, Sosman JA, Sznol M, et al. Atelizumab, an antiprogrammed death-ligand 1 antibody, in metastatic renal cell carcinoma: long term safety, clinical activity, and immune correlates from a phase Ia study. J Clin Oncol 2016; 34:833-842.
10. Brahmer JR, Tykodi SS, Chow L, et al. Safety and activity of anti-PDL-1 antibody in patients with advanced cancer. N Engl J Med 2012; 366:2455-2465.
11. Sanlorenzo M, Vujic I, Daud A, et al. Pembrolizumab cutaneous adverse events and their association with disease progression. JAMA Dermatol 2015; 151:1206-1212.
12. Topalian SL, Hodi S, Brahmer JR, et al. Safety, activity and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366:2443-2454.
13. Minkis K, Garden BC, Wu S, et al. The risk of rash associated with ipilimumab in patients with cancer: a systematic review of the literature and meta-analysis. J Am Acad Dermatol 2013; 69:e121-e128.
14. Hamid O, Robert C, Daud A, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013; 369:134-144.
15. Hua C, Boussemart L, Mateus C, et al. Association of vitiligo with tumor response in patients with metastatic melanoma treated with pembrolizumab. JAMA dermatol 2016; 152:45-51.
16. Lo JA, Fisher DE, Flaherty KT. Prognostic significance of cutaneous adverse events associated with pembrolizumab therapy. JAMA Oncol 2015; 1:1340-1341.
17. Wolchok JD, Kluger H, Callahan MK, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013; 369:122-133.
18. Postow MA, Chesney J, Pavlick AC, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 2015; 372:2006-2017.
19. Herbst RS, Kim DW, Felip E, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1 positive, advanced non-small-cell lung cancer (Jeynote-010): a randomized controlled trial. Lancet 2015. [Epub ahead of print]
20. Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell carcinoma. N Engl J Med 2015; 373:1627-1639.
21. Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of nonsmall-cell lung cancer. N Engl J Med 2015; 372:2018-2028.
22. Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 2015; 373:1803-1813.
23. Ansell SM, Lesokhin AM, Borrello I, et al. PD-1 blockage with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med 2015; 372:311-319.
24. Weber JS, Kä hler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol 2012; 30:2691-2697.
25. Schaberg KB, Novoa RA, Wakelee HA, et al. Immunohistochemical analysis of lichenoid reactions in patients treated with anti-PD-L1 and anti-PD-1 therapy. J Cutan Pathol 2016; 43:339-346.
26. Belum VR, Sibaud V, Lamant L, et al. Oral lichenoid mucositis in cancer patients during nivolumab therapy: a case-series. Cancer Immunol Res (in press).
27. Joseph RW, Cappel M, Goedjen B, et al. Lichenoid dermatitis in three patients with metastatic melanoma treated with anti-PD-1 Therapy. Cancer Immunol Res 2015; 3:18-22.
28. Matsumara N, Ohtsuka M, Kikuchi N, et al. Exacerbation of psoriasis during nivolumab therapy for metastatic melanoma. Acta Derm Venereol 2016; 96:259-260.
29. Kato Y, Otsuka A, Miyachi Y, et al. Exacerbation of psoriasis vulgaris during nivolumab for oral mucosal melanoma. J Eur Acad Dermatol Venereol 2015. [Epub ahead of print]
30. Ohtsuka M, Miura T, Mori T, et al. Occurrence of psoriasiform eruption during nivolumab therapy for primary oral mucosal melanoma. JAMA Dermatol 2015; 151:797-799.
31. Totonchy MB, Ezaldein HH, Ko CJ, et al. Inverse psoriasiform eruption during pembrolizumab therapy for metastatic melanoma. JAMA Dermatol 2015. [Epub ahead of print]
32. Johnson DB, Sullivan RJ, Ott PA, et al. Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders. JAMA Oncol 2016; 2:234-240.
33. Kim DS, Je JH, Kim SH, et al. Programmed death ligand 1, 2 expressions are decreased in the psoriatic epidermis. Arch Dermatol Res 2015; 307:531-538.
34. Abdel-Rahman O, Elhalawani H, Fouad M. Risk of cutaneous toxicities in patients with solid tumors treated with immune checkpoint inhibitors: a metaanalysis. Future Oncol 2015; 11:2471-2484.
35. Teulings HE, Limpens J, Jansen SN, et al. Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis. J Clin Oncol 2015; 33:773-781.
36. Jackson LK, Johnson DB, Sosman JA, et al. Oral health in oncology: impact of immunotherapy. Support Care cancer 2014; 23:1-3.
37. Carlos G, Anforth R, Chou S, et al. A case of bullous pemphigoid in a patient with metastatic melanoma treated with pembrolizumab. Melanoma Res 2015; 25:265-268.